Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts

• Published in: Cancer Immunology Immunotherapy Vol. 32; no. 2; pp. 137 - 142
• Main Authors: KOPPER, L, BANKFALVI, A, MIHALIK, R, GLANT, T. T, TIMAR, J
• Format: Journal Article
• Language: English
• Published: Berlin Springer 1990; Springer-Verlag
• Subjects: Animals; Antibodies, Monoclonal - immunology; B-Lymphocytes - immunology; Biological and medical sciences; Biomarkers, Tumor; Cartilage - immunology; Chondroitin Sulfate Proteoglycans - immunology; DNA - metabolism; Flow Cytometry; Fluorescent Antibody Technique; Host-tumor relations. Immunology. Biological markers; Humans; Immunophenotyping; Lymphoma, B-Cell - immunology; Lymphoma, Non-Hodgkin - immunology; Medical sciences; Mice; Mice, Inbred BALB C; Original; Propidium - metabolism; Proteoglycans - immunology; Transplantation, Heterologous; Tumor Cells, Cultured; Tumors; Human; Proteoglycan; Rodentia; Biological marker; Malignant hemopathy; B-Lymphocyte; Monoclonal antibody; Heterotransplantation; Non Hodgkin lymphoma; Vertebrata; Phenotype; Mammalia; Cell line; Mouse; Animal; Tumor cell
• DOI: 10.1007/BF01754211
• ISSN: 0340-7004

A family of mono- and polyclonal antibodies raised against proteoglycans or their "subcomponents" served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 greater than HT 117 greater than HT 130 greater than B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.